Translational Oncology Partnership Program
Overview
The mission of the Translational Oncology Partnership Program at Memorial Sloan Kettering Cancer Center is to accelerate oncology research and development by leveraging our clinical and scientific expertise, external collaborations, and cutting-edge technologies.
Key priorities include:
- Biomarker Development Program: A collaborative research initiative focused on discovering and validating predictive and prognostic biomarkers
- Developing and validating high-throughput tools for screening and disease monitoring
- Expanding access to precision oncology worldwide
Through strategic research partnerships with academic and industry collaborators, the program aims to advance promising discoveries into preclinical validation and early-phase clinical biomarker development. This will help bridge the gap between the bench and the bedside, with the goal of delivering more effective personalized therapies.
For MSK faculty, this program provides a centralized platform that supports collaborative translational research.
The program is available as a resource for MSK researchers across departments and disease management teams. The program’s infrastructure includes our personnel, who have expertise in:
- Communicating among internal stakeholders to execute collaborative research projects
- Engaging with and managing external stakeholders
- Managing innovative workflows for samples and data acquisition
Our Work
- Biomarker Development Program and Liquid Biopsy Technologies
- Translational Research Infrastructure for Partnership and Integration
- National and International Collaborations for Precision Oncology
For inquiries related to the program, please reach out to Kaylie Johnson at [email protected].
People
Members
